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Griscelli syndrome (GS) is a rare autosomal recessive disorder caused by mutation in the MYO5A (GS1, Elejalde), RAB27A
(GS2) or MLPH (GS3) genes. Typical features of all three subtypes of this disease include pigmentary dilution of the hair and skin
and silvery-gray hair. Whereas the GS3 phenotype is restricted to the pigmentation dysfunction, GS1 patients also show primary
neurological impairment and GS2 patients have severe immunological deficiencies that lead to recurrent infections and
hemophagocytic syndrome. We report here the diagnosis of GS2 in 3-year-old twin siblings, with silvery-gray hair, immunode-
ficiency, hepatosplenomegaly and secondary severe neurological symptoms that culminated in multiple organ failure and death.
Light microscopy examination of the hair showed large, irregular clumps of pigments characteristic of GS. A homozygous
nonsense mutation, C-T transition (c.550C>T), in the coding region of the RAB27A gene, which leads to a premature stop codon
and prediction of a truncated protein (R184X), was found. In patient mononuclear cells, RAB27A mRNA levels were the same
as in cells from the parents, but no protein was detected. In addition to the case report, we also present an updated summary on
the exon/intron organization of the human RAB27A gene, a literature review of GS2 cases, and a complete list of the human
mutations currently reported in this gene. Finally, we propose a flow chart to guide the early diagnosis of the GS subtypes and
Chédiak-Higashi syndrome.
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Introduction
Griscelli syndrome (GS) is a fatal autosomal recessive
disorder, first described by Griscelli et al. (1) as partial
albinism associated with immunodeficiency. It is a rare and
not widely known disease, and its clinical features such as
silvery-gray hair and immunological dysfunction resemble
Chédiak-Higashi syndrome (CHS), an erythrophagocytic
lymphohistiocytosis (2). However, light microscopy exam-
ination of the scalp hair is an easy way to differentiate
these two syndromes. Hair shafts from CHS patients re-
veal small regular melanin aggregates, whereas in GS
large clumps of pigment irregularly distributed are found
(3,4). In addition, electron microscopic examination of a
skin biopsy from CHS patients reveals giant melanosomes
in both melanocytes and keratinocytes (2). In contrast, GS
patients show melanocytes with a massive accumulation
of mature melanosomes with adjacent keratinocytes con-
taining only sparse melanosomes (3).
GS was classified into three different subtypes, all of
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which show similar pigment dilution. In addition to pigment
problems, type 1 (GS1 [MIM 214450], Elejalde), caused by
mutation in the MYO5A gene, is associated with severe
primary neurological impairment such as developmental
delay and mental retardation (4). The MYO5A gene en-
codes the motor protein myosin-Va, which is highly ex-
pressed in the brain and plays a very important function in
neurons (5-7).
The second type (GS2 [MIM 607624]), caused by mu-
tation in RAB27A gene (8,9), is associated with a primary
immunodeficiency due to an impairment of T cell and
natural killer cytotoxic activity, which leads to susceptibility
to repeated infections, and culminates in a life-threatening
condition known as hemophagocytic syndrome or hemo-
phagocytic lymphohistiocytosis (HLH), usually triggered
by viruses and marked by periods of fever, hepatospleno-
megaly and pancytopenia. HLH has been characterized by
an unremitting polyclonal CD8+ T-cell expansion, and lym-
phocytic infiltration of visceral tissues that leads to macro-
phage activation (hemophagocytosis) and the deleterious
release of several cytokines, including interferon γ, inter-
leukins (IL-1, IL-6, IL-18) and tumor necrosis factor-α,
which sustains the macrophage activation and leads to
hyperinflammation, involving progressive deterioration of
the central nervous system, and multiple organ failure (10-
13). RAB27A gene encodes the small GTPase protein
Rab27a, which is required for peripheral anchorage of
melanosomes in melanocytes, as well as exocytosis of
cytolytic granules in cytotoxic T lymphocytes and natural
killer cells or secretory vesicles in endocrine cells (11,12,14-
17).
The third type (GS3 [MIM 609227]), caused by muta-
tion in the melanophilin gene (MLPH), is restricted to
hypopigmentation defects (18). Another mutation whose
phenotype is restricted to the pigmentation defect is the
specific deletion of the MYO5A exon F (18). The pigment
dilution common to GS1, GS2 and GS3 is due to the
absolute requirement for these three proteins, myosin-Va,
Rab27a and melanophilin, which together form a heterotri-
meric protein complex, in melanosome transport (14,19).
Thus, a defect in any one of these proteins leads to the
same pigmentary defect. In contrast, Rab27a appears to
use other molecules, such as the recently uncovered
Munc13-4 [FHL3 (MIN 608898)] as effector in cytotoxic-T-
lymphocytes and natural killer cells for the exocytosis of
lytic granules (20).
Case Report
This research was part of a project approved by the
Human Research Ethics Committee of our institution.
The patients were identical twins (Figure 1A), the first
children of a non-consanguineous marriage born to healthy
parents after an uncomplicated pregnancy and delivery.
The children had normal neuropsychomotor development
during the first year of age. At three years of age, one of
them was hospitalized with symptoms of encephalitis,
confirmed by the presence of a hypersignal in the periven-
tricular white matter of the brain by magnetic resonance
imaging (MRI, data not shown), and died abruptly. About
nine months later, his twin brother presented fever associ-
ated with axial and appendicular ataxia and was admitted
to the hospital with suspected cerebellitis. Laboratory evalu-
ation consisting of a blood count, hepatic function analysis
and metabolic screening was normal. Light silvery-gray
colored scalp hair and eyebrows with normal pattern and
texture were noted (Figure 1A). Cerebrospinal fluid showed
discrete pleocytosis with a predominance of mononuclear
cells and also a discrete increase of proteins. FLAIR (fluid-
attenuated inversion-recovery) MRI of the encephalon
showed lesion at the right cerebellar hemisphere with
capturing contrast, and a small area of hypersignal in the
supratentorial white matter (Figure 1B-D). Treatment with
acyclovir was initiated and continued for 21 days. Blood
and hair of this patient and his parents were collected for
molecular or microscopy analyses as described in the next
sections.
Two months after his discharge from the hospital, the
patient started to have fever again. Another blood count
showed thrombocytopenia. The child was hospitalized
again and his clinical features progressed to pancytope-
nia, hepatosplenomegaly, fever and coma. After removal
of sedative medicines, the child remained in a persistent
vegetative state, with continuous fever, hepatosplenomeg-
aly, tetraparesis, and axial hypotonia. He showed sym-
metrical osteotendineous reflexes and lack of the
photomotor reflex, and was treated with corticoid and
cyclosporine. However, he did not respond to treatment
and died.
Material and Methods
Hair imaging
Hair shafts were mounted on slides with Permount
(Fischer Scientific, USA), covered with a coverslip and
analyzed directly and photographed on bright field micros-
copy using a digital camera.
Peripheral blood mononuclear cells isolation
Peripheral blood mononuclear cells (PBMC) were sepa-
rated from whole heparinized blood by the Ficoll-Hypaque
density-gradient technique (Hystopaque 1077, Sigma Al-
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drich, USA). Samples of cells were cultured in RPMI 1640
medium (Invitrogen, USA), supplemented with 2 mM L-
glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10
mM HEPES, and 10% fetal calf serum (FCS), in a humidi-
fied atmosphere of 5% CO2, at 37°C. Cultured cells were
frozen in 90% FCS/10% dimethyl sulfoxide and stored in
liquid nitrogen.
Genomic DNA extraction
DNA was extracted from PBMC by a standard phenol-
chloroform technique.
Polymerase chain reaction amplification
For the polymerase chain reaction (PCR) amplification
of the RAB27A gene from the genomic DNA of the patient
and his parents, we used the Elongase® Enzyme Mix
(Invitrogen) and primers flanking coding regions of the five
coding exons of the RAB27A gene (8). The coding exons
are numbered 2-6 according to the reference sequence
(RefSeq) gene NM_004580 (NCBI and UCSC genome
browser). The sequence of the pairs of primers used to
amplify these regions are: 5'TCATACAACCCGT
AGACATACA3'/5'TGTTGACTTAACGATTACATTTTT3';
5'TTGTTTTCTCTTTCACTTTG3'/5'TTTTCCCTTTCC
TTCAG3'; 5'GCTGAAGGCATTGCTTGT3'/5'AGATCT
CCTCCAAAACGATT3'; 5'TTTTGCATGTATTGTTCA
C T G A 3 ' / 5 ' T G G C T G A G G T T T T G C T T T A 3 ' ;
5 'TGTCTTCCAGAATCCCCTACT3 ' /5 'ATGCCC
ATTAATCTCTCACTGT3'.
Mutation detection
PCR products were sequenced directly using the Big
DyeDeoxy terminator kit and an ABI 3100 sequencer (Ap-
plied Biosystems, USA). Sequences were aligned with the
RAB27A genomic contig NT_010194.16 and human NCBI
RAB27A RefSeq mRNAs.
Reverse transcription and polymerase chain reaction
Total RNA and protein were extracted simultaneously
from the PBMC of the patient and his parents and from
Jurkat lymphocytes using the Trizol® reagent (Invitrogen),
according to the protocol suggested by the manufacturer.
For reverse transcription (RT), we used the Superscript II
enzyme (Invitrogen) and for PCR amplification of the target
cDNA, the Elongase or Taq DNA polymerase (Invitrogen).
The sequences of the pairs of primers used for amplifica-
tion of RAB27A, MYO5A, and  ß-actin cDNA fragments
are: 5'GATAAGCCAGCTACAGATGCA3'/5'TAATGGGG
ATGGTGAGAAGCA3'; 5'AGTCTCTGTGTCGTTCATT
CG3'/5'CCTGTATGTAAACTCACGGTA3'; 5'GGCATCG
TGATGGACTCCG3'/5'GCTGGAAGGTGGACAGCGA3'.
Immunoblotting
For immunoblotting, we used a mouse monoclonal
antibody to human Rab27a (Transduction Laboratories,
USA; catalog R52320), which recognizes a 25-kDa poly-
peptide.
Results
Light microscopy analysis of the hair revealed large
clumps of pigments in the hair shaft of the patient, typical of
GS, in contrast with the even pigment distribution in normal
hair shafts and the typical punctuating pattern seen in the
hair from a CHS patient (Figure 1E-H). A skin biopsy could
not be performed. In order to determine the mutation and to
confirm the GS2 subtype, we amplified by PCR and se-
quenced the five exons comprising the coding region of the
RAB27A gene and part of the flanking introns (Figure 2). At
least 3 sequencing runs were performed directly from the
PCR product for each fragment. Good quality consensus
sequences were extracted and a single nonsense muta-
tion, a C-T transition, c.550C>T, mapping to exon 6 was
found (Figure 2D). This mutation is predicted to cause a
premature translation termination instead of arginine (R) at
position 184 of Rab27a, truncating the protein by 38 amino
acid residues at the C-terminal (wild-type Rab27a is pre-
dicted to have 221 amino acid residues).
RT-PCR amplification allowed us to confirm the pres-
ence of RAB27A mRNA in RNA samples extracted from
PBMC of the patient as well as of the parents (Figure 3),
demonstrating that this mutant form of mRNA is not un-
stable. Since myosin-Va functions in complex with Rab27a
and is the gene associated with GS1, we also checked for
any abnormality in the expression of this gene. RT-PCR
showed equivalent amplification of a cDNA fragment from
the patient and his parents, indicating that there was
probably no alteration in the expression of this gene (Fig-
ure 3). Western blot showed the detection of a 25-kDa
polypeptide, the expected apparent molecular mass for
Rab27a on SDS-PAGE, for the father and the mother,
but only a very faint signal for the patient (Figure 3).
Although the predicted truncation caused by the mutation
would probably shift the relative molecular mass to near
21 kDa, we did not detect any bands in a lower molecular
weight range in the patient’s lane. A nonspecific band (~50
kDa), which is being used here as a loading control,
indicates that a lower amount of total protein was loaded
in the patient lane, but this does not appear to account for
the greatly diminished signal for Rab27a in the patient
sample, leading to the suggestion that the mutant protein is
either susceptible to proteolysis or not efficiently trans-
lated.
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Figure 1. Typical features of Griscelli syn-
drome. A, The twin patients. Note the
very light silvery-gray color of the hair
and eyebrows. B-D, FLAIR-MRI obtained
from the encephalon of one of the pa-
tients, showing a hypersignal (arrows) in
the right cerebellar hemisphere and in
the cerebral white matter: axial sections
(B, C) and sagittal section (D). E-H, Light
micrographs of the hair, showing the large
clumps of pigment irregularly distributed
in the hair shafts of the patient (E), in
contrast with fine, well-distributed pig-
ment in normal controls from persons with
brown (F) and blond (G) hair, and the
punctuating pattern of the pigment in a
hair shaft from a Chédiak-Higashi patient
(H), who was also attended in our health
service. [Color figure can be viewed in
the online issue, which is available at
www.interscience.wiley.com].
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Figure 2. The RAB27A gene, PCR products and detection of a nonsense mutation. A, Schematic representation of the exon/intron
organization of the RAB27A gene based on the indicated NCBI RefSeqs and expressed sequence tags (ESTs). Exons within the
untranslated (UTR) and coding regions are represented by filled-in and empty boxes, respectively. According to four NCBI RefSeqs
available, the RAB27A gene comprises 9 exons (black and empty boxes) spanning 86,200 bp within the indicated interval in the minus
strand, chromosome 15q21.3 (genomic contig NT_010194). Also, additional exons (gray boxes) are supported by ESTs in the 5’UTR,
or even upstream from RAB27A genomic region (not indicated; see Discussion). The coding region of 666 bp is constant among the
transcript variants. Exons identified by Tolmachova et al. (22) are numbered accordingly. Exon 1a is present in all RefSeqs while the
other five exons within the UTR are alternatively spliced, even though exon 1a also shows transcribed segments of alternative lengths
(223 or 120 bp) in different mRNA sequences, suggesting alternative splicing site usage. *Indicates that 88 or 51 bp are the lengths of
these exonic segments in RefSeqs NM_183235 and NM_183236, respectively, which are probably incomplete. B, Schematic of the
most abundantly expressed isoform, represented by RefSeq gene NM_004580 (transcript variant 1) (27) depicting the regions
amplified by PCR. C, PCR products of the indicated regions (B) obtained from the genomic DNA, stained with ethidium bromide on
agarose gels, for the father (F), mother (M) and the patient (P). L = length marker (ladder): O’Gene Ruler™ (Fermentas, Burlington,
ON, Canada). D, Sequence electropherograms showing the c.550C>T mutation (arrow) in homozygous form in the patient and
heterozygous in his parents. This mutation predicts a premature translation termination instead of arginine (R) at position 184 of the
Rab27a protein. Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.
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Figure 3. RAB27A and MYO5A mRNA, but not the Rab27A
protein, are normally expressed in peripheral blood mononuclear
cells (PBMC) of the patient. Reverse transcription and polymer-
ase chain reaction (RT-PCR) for amplification of cDNA frag-
ments from RAB27A, MYO5A, and ß-actin as control, were
performed on total RNA extracted from the PBMC of the father
(F), the mother (M), and the patient (P), and the Jurkat CD4+
lymphoblast cell line (J). RT using oligo-dT priming and DNase
treatment were performed prior to PCR amplification. A PCR
control reaction was performed on one of the RNA samples,
DNase treated without previous RT (C). Western blot (WB) con-
taining total protein extracts of PBMC from the father (F), the
mother (M) and the patient (P) immunoreacted with a monoclon-
al antibody to Rab27a and developed by chemiluminescence.
An unspecified 50-kDa band is used here as an internal loading
control for normalization.
Discussion
A mutation identical to the one shown here was previ-
ously reported in two brothers from a non-consanguineous
Mauritian family (8) and in an Indian child (21), but this is
the first time that protein expression was analyzed for this
mutation. The inability to detect a protein leads to the
conclusion that Western blot can be used as a tentative
rapid assay to associate the disease with RAB27A.
A total of 101 cases with the clinical and laboratory
features of GS2 have been reported in the literature [see
OMIM (Online Mendelian Inheritance in Man) 607624 and
603868, and for a list of references on GS2 case reports,
which have not identified the mutation and are not cited in
OMIM, see our WEB resource at FMRP.USP cited in the
next section]. Amongst these 101 cases, 54 GS2 patients
had their mutations sequenced, totaling the occurrence of
27 different mutations in this locus associated with GS2
plus 1 heterozygous mutation not associated with this
disease (Table 1). The Human Gene Mutation Database at
the Institute of Medical Genetics in Cardiff (HGMD-
BIOBASE) resource currently refers to only 13 mutations.
The exon numbering of RAB27A is currently done in accor-
dance to the nomenclature proposed by Tolmachova et al.
(22), when two 5’UTR exons (named 1a and 1b) had been
detected; however, a much higher complexity has been
revealed by a large number of expressed sequences match-
ing this locus, generating discrepancies in the literature.
This led us to tentatively present an updated compilation of
exon/intron organization for the RAB27A gene predicted
from alignments of expressed sequences with the genom-
ic contig (Figure 2). In addition to NM_004580 (transcript
variant 1), three other RAB27A NCBI RefSeqs were as-
sembled and annotated as transcript variants 2 to 4, sup-
ported by full open-reading frame mRNA sequences, which
shows 3 alternatively spliced exons in the 5’UTR plus an
alternative splice site usage in exon 1a, resulting in alter-
natively spliced regions of 223 or 120 bp in length for this
exon. Furthermore, two novel exons not included in the
NCBI RefSeqs, represented by gray bars in Figure 2, are
supported by expressed sequence tags (ESTs). Interest-
ingly, there are also at least two independent ESTs
(DA795745, DR156180), which support the inclusion in
this gene of two novel exons located upstream from the
genomic region of RAB27A such that they overlap with the
PIGB (phosphatidylinositol glycan - class B) gene, impli-
cating in further structural or transcriptional complexity to
this locus, whose relevance will require further investiga-
tion to clarify. Regardless of such mRNA diversity due to
multiple alternative splices in the 5’UTR and alternative
poly-A addition signals in the 3’UTR, the coding region of
the gene is rather constant. RAB27A is an easy gene to
scan by sequencing due to its small size and because all
detected mutations associated with GS2, except for two
large deletions, are restricted either to the coding region or
near splice sites.
The prognosis and treatment of GS depend on the type
of the condition. GS is most commonly diagnosed between
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the ages of 4 months and 7 years (3). There is no cure for
GS1 and the life of the patients depends on the severity of
the neurological impairment. GS3 does not need treatment
since it involves altered pigmentation only. The treatment
of choice for GS2 is bone marrow transplantation (BMT),
which should be done as early as possible. The case of the
two monozygotic twins reported here is an example of how
important it is to prepare the health care services to recog-
nize this disease and propose effective treatment in time.
In this case, the first patient died in the accelerated he-
mophagocytic syndrome phase more than 6 months ahead
of his brother, who at that time was in perfect physical
condition for a BMT. Cases of successful BMT are re-
Table 1. Summary of human mutations reported in RAB27A.
Mutationa Locationb Predicted effect Occurrence Origin References
c.550C>T Exon 6 R184X 2c Mauritius 8
1 India 21
2c Brazil    Present study
c.217T>G Exon 3 W73G 2 Turkey 8,28
c.389T>C Exon 5 L130P 1 Turkey 8
c.454G>C Exon 5 A152P 1 Turkey 8
c.346C>T Exon 5 Q116X 1 Turkey 28
c.149delG Exon 2 R50fsX84 11 Turkey 8,28,29
1 Germany 29
c.510delAAGCC Exon 6 Q172fsX173 2 Turkey 8
1 Armenia 24
2c Turkey 30
1 Iran 31
1 Italy 25
c.154del154-343 Exon 3 + 4 V52fsX65 3 North Africa 8
c.400delAA Exon 5 K134fsX135 1 USA 8
c.51del CT Exon 2 S18fsX32 1 Arabic 32
67.5 kb del Exon 1-5 null 1 Palestine 33
c.352C>T Exon 5 Q118X
1 Brazil 26c.467 +1G>C Intron 5 G156fs
c.467 +1G>C Intron 5 G156fs 1 Brazil 8
c.239 +3A>G Intron 3 R80fs 1 North Africa 8
c.259G>C Exon 4 A87P
1 Germany 29
27.8 kb del Exon 2-5 null
c.598C>T Exon 6 R200X 1 Asiatic 34
Not shown 1 India 35
c.149G>C Exon 2 Arg50fsX34 1 Iran 31
c.131T>C Exon 2 Ile44Thr 1 Iran 31
c.340delA Exon 4 Ile114X 1 Iran 31
c.514delCAAGC Exon 6 Gln172fsX1 5 Iran 31,36
c.400A>G Exon 5 K134E 3 Jordan 37
c.127G>A Exon 2 G43S 1 Afghanistan 38
c.550C>T Exon 6 R184X
1 Denmark 38
c.598C>T Exon 6 R200X
c.148-149delAGinsC Exon 2 R50fsX84 1d Germany 39
aNumbering is based on the coding sequence (CDS), which is constant in all 4 RAB27A transcript variants (NM_004580, NM_183234,
NM_183235 and NM_183236). bExons 2-6 are the coding exons of RAB27A (see Refs. 8,22,33 and Figure 2). cIdentical twin siblings.
fs = frameshift, X = stop codon. dPatient with Hermansky-Pudlack syndrome carrying this heterozygous mutation in RAB27A, as well
as his healthy father.
ported and immunosuppressive therapy is also used to
maintain the patient stable as a palliative therapy or to
induce remission until BMT (3,23-25). Bizario et al. (26)
showed rescuing of cytotoxic T lymphocyte activity using a
retroviral vector to mediate the transfer of RAB27A gene,
opening an alternative possibility for GS2 treatment. Al-
though it demands further studies, gene therapy may
prove to be an excellent way to treat GS and other genetic
immune disorders. Recent progress has also uncovered
the molecular basis of other classes of familial HLH (10-
12), even the ones not involving pigmentation defects,
improving the possibilities for early diagnosis and treat-
ment of this large group of life-threatening diseases.
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Figure 4. A flow chart to guide the early diagnosis of Griscelli (GS) and Chédiak-Higashi syndromes (CHS). The flow chart
summarizes the steps to follow after signs of silvery-gray hair are detected in an infant. The steps include examinations required for
differential and complementary diagnosis and point towards the candidate gene for sequencing. Molecular diagnosis is then
mandatory to provide information necessary for the physician to adopt effective treatment when available. Bone marrow transplanta-
tion offers the possibility of effective treatment for CHS and GS2 patients. FLAIR = fluid-attenuated inversion-recovery; HLH =
hemophagocytic lymphohistiocytosis.
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Finally, as shown in Figure 4, a flow chart was created
to summarize the steps to follow once signs of silvery-gray
hair are detected in an infant. GS and CHS can be promptly
distinguished by light microscopy of hair shafts, which is
very easy to perform. Complementary exams, such as light
microscopy of blood smear and of a skin biopsy, may also
be adopted in searching for the presence of giant lyso-
somes/endosomes (inclusion bodies) in leukocytes or gi-
ant melanosomes in melanocytes as characteristics of
CHS and, conversely, the absence of giant granules in
leukocytes but the presence of a large accumulation of
normal mature melanosomes within the melanocytes are
typical features of GS. Subsequently, FLAIR-MRI of the
brain might also be helpful in the interpretation of the
degree of neurological defects. Primary neurological defi-
ciency marked by profound, congenital cerebellar atrophy
is associated to GS1 (Elejalde) (27), and secondary neuro-
logical damage involving the white matter, due to leuko-
cyte infiltration that occurs during HLH manifestation, is
associated with GS2 and CHS. Finally, sequencing the
candidate gene is mandatory to identify the molecular
basis of the disease, supporting physicians to adopt effec-
tive treatment, which is available for GS2 and CHS pa-
tients as BMT. GS1 patients should receive family support
and palliative health care and GS3 patients have no need
for treatment. Concluding, all infants with silvery-gray hair
should be evaluated before any complicated symptoms
appear. The urgency of an early diagnosis is justified by
the possibility of saving lives in the case of GS2 and CHS.
Thus, a health program directed at the neonatal diagnosis
of these diseases should be implemented in most coun-
tries without much effort.
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